pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,386 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints892BioPharma Dive344BioSpace307Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7601Rare Disease1873Cardiology1743Immunology1478Hematology1321Vaccines1197Pulmonology
  • US pushes Germany on drug pricing while FDA faces turmoil and biotech trials advance, says Pharmalittle roundup
    The newsletter notes that U.S. lawmakers are intensifying pressure on Germany to lower the prices of pharmaceuticals, a move that could reshape cross-border pricing negotiations. At the same time,…
    STAT · 3mo agoNeutral↗ source
  • Alcohol’s deadly toll is overlooked as a public-health crisis, STAT explores why
    STAT’s weekly video series highlighted that alcohol kills more Americans than any other drug, yet it is rarely framed as a public‑health emergency. The contrast between its mortality impact and pub…
    STAT · 3mo agoNeutral↗ source
← prev
page 78 of 96
next →
fda recalls70
fda medwatch60
fda press38
1186
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism474
Infectious Disease444
GU experts poll top abstract topics for ASCO 2026 meeting
A poll of genitourinary oncology specialists was conducted to gauge interest in upcoming ASCO 2026 abstracts. Participants used OncLive’s social media platform to nominate the abstracts they expec…
onclive · 3mo agoNeutral↗ source
  • Roswell Park Researchers Join 2026 World Indigenous Cancer Conference
    Roswell Park Comprehensive Cancer Center staff took part in the 2026 World Indigenous Cancer Conference, a global gathering focused on cancer issues affecting Indigenous peoples. The conference br…
    onclive · 3mo agoPositive↗ source
  • Basking Biosciences appoints former Pulmocide chief medical officer Lance Berman
    Basking Biosciences announced the addition of Lance Berman as its new chief medical officer. The appointment was highlighted in a recent industry column that tracks personnel changes. Berman comes…
    STAT · 3mo agoNeutral↗ source
  • OncLive launches weekly quiz on recent FDA oncology approvals
    OncLive released a weekly news quiz dated May 15, 2026, inviting readers to test their knowledge of recent oncology developments. The quiz focuses on three new FDA approvals in the oncology space…
    onclive · 3mo agoNeutral↗ source
  • Remembering Craig Venter: The Complex Legacy Behind the Human Genome Race
    Former NIH archivist Zachary Utz reflects on the recent death of Craig Venter, a prominent figure in genomics known for challenging conventional scientific approaches. Venter’s private company Cel…
    STAT · 3mo agoNeutral↗ source
  • Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancer
    A recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
    onclive · 3mo agoPositive readoutPositive↗ source
  • BeOne secures FDA approval for lymphoma therapy
    BeOne received FDA approval for its lymphoma therapy, a notable achievement in a crowded therapeutic area. The agency’s review concluded that the treatment meets safety and efficacy standards, pla…
    STAT · 3mo agoApprovalPositive↗ source
  • Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for Duchenne
    Regenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…
    BioPharma Dive · 3mo agoRegulatoryPositive↗ source
  • Regenxbio reports successful Duchenne gene therapy trial, clearing path to FDA filing
    Regenxbio announced that its experimental gene therapy for Duchenne muscular dystrophy met its primary endpoints in a recent clinical trial, producing sufficient levels of a truncated muscle protei…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Supreme Court blocks restrictions, keeps mifepristone available through pharmacies and mail
    Supreme Court on Thursday issued an order that maintains women's ability to obtain the abortion medication mifepristone without requiring an in-person doctor visit. The decision overturns a lower-…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypes
    Ibrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Create Medicines secures $122M Series B to advance in vivo CAR-T therapies
    Create Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanoma
    A Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 data
    Biogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian Cancer
    AVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…
    onclive · 3mo agoPositive readoutPositive↗ source
  • FDA commissioner Marty Makary exits, acting head Kyle Diamantas named as podcast discusses impact and Senate health race
    The Readout Loud podcast episode focused on health politics, featuring a discussion of FDA commissioner Marty Makary's departure. Hosts examined why Makary is leaving, which of his policies might…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Rintatolimod added to pembrolizumab and cisplatin yields 50% response rate in recurrent ovarian cancer
    A clinical study evaluated the combination of rintatolimod, pembrolizumab and cisplatin in patients with recurrent ovarian cancer. The regimen produced an objective response rate of 50%, indicatin…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Stage IV Breast Cancer Cases Rise Over Past Decade, Dana-Farber Study Shows
    A recent analysis by Dana-Farber Cancer Institute examined breast cancer diagnoses over the past ten years. The researchers found that the number of patients diagnosed with stage IV disease has ri…
    onclive · 3mo agoNeutral↗ source
  • Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapy
    Biogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026
    Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…
    onclive · 3mo agoNeutral↗ source
  • Triplet immunotherapy improves survival in HER2‑positive gastric cancer, suggesting broader immune activation
    New data from a study of HER2‑positive gastric cancer patients evaluated a triplet immunotherapy regimen. The analysis compared the combination against standard approaches and focused on overall su…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questions
    The HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer. These efficacy finding…
    onclive · 3mo agoPositive readoutPositive↗ source
  • CREATE Medicines raises $122 million to advance CAR-T candidates into human trials
    CREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…
    STAT · 3mo agoDealPositive↗ source